GenEng News  Sep 21  Comment 
PDL BioPharma said today it has acquired, for $65 million, portions of royalties and commercial milestone payments tied to expected sales of AcelRx Pharmaceuticals’ Zalviso™ (sufentanil sublingual tablet system) by its commercial partner...
Benzinga  Sep 21  Comment 
Atmel Corporation (NASDAQ: ATML) shares rose 18.57 percent to $8.62 in pre-market trading after Dialog Semiconductor Plc (OTC: DLGNF) announced its plans to acquire Atmel for around $4.6 billion. Uniqure NV (NASDAQ: QURE) shares climbed 13.80...
newratings.com  Sep 21  Comment 
VIENNA (dpa-AFX) - AcelRx Pharmaceuticals, Inc. (ACRX) Monday announced the sale and monetization of royalties of Zalviso in European Union by its commercial partner Grunenthal GmbH to PDL BioPharma (PDLI) in a deal worth $65 million. As per the...
newratings.com  Sep 10  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - AcelRx Pharmaceuticals Inc.'s (ACRX) phase III trial of ARX-04 (sufentanil sublingual tablet, 30 mcg) in patients with moderate-to-severe acute pain following ambulatory abdominal surgery has met primary and...
FierceBiotech  Sep 9  Comment 
Days after the FDA reiterated its demand for a new trial of AcelRx's pain drug Zalviso before it can reconsider a marketing application, the small biotech says it has garnered positive data from its late-stage study of another pain remedy in the...
Benzinga  Sep 9  Comment 
Akebia Therapeutics Inc (NASDAQ: AKBA) shares rose 82.46 percent to $14.25 in pre-market trading after announcing positive top-line results from a Phase 2 study of Vadadustat "in Dialysis Patients with Anemia Related to Chronic Kidney Disease."...
Benzinga  Sep 8  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares fell 6.76 percent to $4 in pre-market trading after gaining 4.13 percent on Friday. Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE: YGE) shares dropped 13.31 percent to $0.63 in pre-market...
Benzinga  Sep 2  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares are down 33 percent year-to-date after having peaked at $9.32 on March 2. HC Wainwright analyst Ed Arce initiated coverage of the company with a Buy rating and a price target of...


AcelRx (NASDAQ:ACRX) is a pharmaceutical company which develops and sells treatments for acute and breakthrough pain. In particular, the product would help with post-operative pain. AcelRx has completed Phase 2 and is preparing to conduct two Phase 3 clinical trials for its lead product.[1]

Acute and breakthrough pain associated with the post-operation period is often treated with intravenous (IV) opioid injections. These tend to have negative side effects due to the usage of morphine. In addition, there can be delivery and programming errors from the complex infusion pumps used to provide the patients with the opioid. AcelRx's lead candidate involves a patient administered dosage sublingual, or below the tongue. AcelRx also uses Sufentanil rather than morphine.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 10, 2011. The company offered 8M shares each for $5. The company originally planned to sell 5.8M shares within the range of $12-$14. This would have made the deal worth $75.4M, but the drop in price brought the total deal to $40M even after the rise in shares sold. The lead underwriter of the deal was Piper Jaffray Companies (PJC). Canaccord Capital (BER:C6U), Cowen Group (COWN), and JMP Group (JMP) acted as comanagers.[3]

Because AcelRx does not have a commercially viable yet, the company is still in the pre-revenue stage. As a result, the company has incurred high Research & Development expenses without making money. For the first 9 months of 2010, AcelRx's net loss was $10.8M, 58% of which was from research and development expenses. [4]


  1. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg1
  2. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Sufentanil NanoTabs" pg1-2
  3. Renaissance Capital - IPO Home "AcelRx prices IPO at $5, below the original $12-$14 range" 11 Feb 2011
  4. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Summary Financial Data" pg10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki